INTRODUCTION
============

Chronic infection with potentially carcinogenic agents is recognized as a major risk factor of human cancer^[@r01],[@r02]^ and was estimated to be responsible for around 2 million new cancer cases worldwide in 2008. The overall population attributable fraction (PAF) for infectious agents was 16.1% worldwide,^[@r03]^ indicating that 16.1% of new cancer cases could be prevented by elimination of such infectious agents. This fraction is higher in developing countries (22.9%) than in developed countries (7.4%).

Asia, which contains over 60% of the world's population, plays an increasingly important role in international economics and trade. As a part of global analysis, the burden of infection-associated cancer in Asia has been estimated.^[@r03],[@r04]^ While the diversity of environment, culture, and economics in different countries contributes to the variety of infectious agents and their prevalence in the general population, the effects of those factors have not been revealed in previous studies.

The aim of the current study is to assess the cancer burden attributable to infection in 13 Asian countries based on review of nation-specific prevalence of carcinogenic infectious agents and comparison of risk estimates between exposure and infection-associated cancer.

METHODS
=======

Geographical areas
------------------

As residential environment, social-economic status, habits, and culture vary in different places among different groups of people, we chose countries and regions with the largest population sizes to obtain reliable and stable estimates, while also taking population representativeness into consideration. With the population data of almost all Asian countries and regions available in GLOBOCAN 2012, we chose a cut-off point of 30 million. As a consequence, 13 countries were included and divided into four areas: East Asia (Korea, China, and Japan), Southeast Asia (Indonesia, the Philippines, Thailand, and Vietnam), Middle South Asia (Bangladesh, India, Iran, and Pakistan), and West Asia (Turkey and Saudi-Arabia), following the geographical definition of the 2012 revision of the United Nations' World Population Prospects.^[@r05]^ Although Iraq was on the list of 13 countries, few studies of infection prevalence in Iraq were available. Subsequently, we substituted Saudi Arabia, a smaller West Asian country with a population of 27 million, for Iraq because more information on infection prevalence was available for Saudi Arabia.

Definition of exposure
----------------------

Infectious agents with sufficient evidence for their carcinogenicity were defined in an IARC monograph series.^[@r02]^ The infectious agents and related cancers used in the current study are listed in Table [1](#tbl01){ref-type="table"}. Other carcinogenetic infectious agents, such as *Schistosoma haematobium* and human T-cell lymphotropic virus type 1 (HTLV-1), were not included in the current analysis because the prevalence of the infectious agents in Asia or the data of cancer incidence and/or mortality were not available in published studies or were only available in low quality studies (eg, studies with small sample sizes or poor study designs).

###### List of group 1 carcinogenic biological agents and related cancers

  ------------------------------------------------------------------
  Infection-associated cancers   Group 1 agents
  ------------------------------ -----------------------------------
  Oral cavity                    HPV

  Oropharynx                     HPV

  Nasopharynx                    EBV

  Noncardia gastric cancer       *Helicobacter pylori*

  cardia gastric cancer          *Helicobacter pylori*

  Anus                           HPV

  Liver                           

   Hepatocellular carcinoma      HBV, HCV

   Cholangiocarcinoma            *Clonorchis sinensis*, HBV, HCV,\
                                 *Opisthorchis viverrini*^a^

  Vulva                          HPV

  Vagina                         HPV

  Cervix uteri                   HPV

  Penis                          HPV

  Hodgkin's lymphoma             EBV

  Non-Hodgkin's lymphoma         HIV-1, HCV

   Burkitt's lymphoma            EBV

  Kaposi's sarcoma^b^            KSHV/HIV-1
  ------------------------------------------------------------------

^a^*Opisthorchis viverrini* is only prevalent in Thailand.

^b^The incidence of Kaposi's sarcoma is low in Asians.

EBV, Epstein-Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; HPV, human papillomavirus; KSHV, Kaposi's sarcoma herpes virus (also known as Human herpes virus type 8).

Prevalence of infectious agents and relative risk of cancers and infectious agents
----------------------------------------------------------------------------------

Searches were conducted in Pubmed, Google Scholar, and Chinese National Knowledge Infrastructure (CNKI) for all published studies in Chinese and English. The keywords of prevalence-oriented searching were "prevalence", the names of infectious agents, and the country names. Prevalence data published between 1997 and 1999 were collected, fixing the exposure time of infectious factors around 1997. The intervals from exposure to the infectious agents to diagnosis of related cancer were all assumed to be 15 years in the current study.^[@r06]^ If the data from 1997--1999 for some countries were not available, we expanded our search to data published between 1995 and 2000. We included case-control studies with large sample sizes only if population-based cross-sectional studies were not available. As a consequence, prevalence data is based on the general population without adjustment for age. In the search for relative risks (RRs), we included keywords of "meta-analysis", "cohort study", "case-control study", and the names of infectious agents and relevant cancers. The priority for data selection was (1) meta-analysis or pooled analysis in Asia; (2) large-scale case-control study in an Asian country; and (3) multinational meta-analysis or meta-analysis from non-Asian countries. For instance, we included (2) only if (1) was not available. The biomarkers of infectious agents were human papillomavirus (HPV) DNA, HPV L1 antibody, serum-antibody against *Helicobacter pylori* (HP), anti-HIV antibody, anti-hepatitis C virus (HCV) antibody, and hepatitis B surface antigen (HBsAg), which are considered to be relatively sensitive and accurate measurements of prevalence in the general population. RRs in these studies are calculated by comparing the probability of developing cancer in an exposed population to that in a non-exposed population (cohort study) or estimated with odds ratios (ORs) in case-control studies. We prioritized results from the latest published studies over older studies because the time effect and newly discovered confounding biases are more likely to be taken into consideration in more recent studies. We assumed that RRs were constant in different countries and adopted generally accepted RRs, which were abstracted from international studies or meta-analysis of worldwide prevalences. Similarly, if the sex-stratified prevalence was not accessible, it was assumed that both sexes were exposed equally to infectious factors, and sex-stratified prevalence was replaced by overall prevalence. The prevalence among patients was adopted when the general prevalence was not available. To account for the differences between general population and patient prevalences, Formula B (which we discuss in the Methods section), was used in PAF calculation.

As 85%--95% of the general population had positive serology tests (IgG) for Epstein-Barr virus (EBV) infection when young,^[@r07],[@r08]^ it was not necessary to match the prevalence of EBV in calculation of cancer burden. As a result, the PAFs of EBV-related cancers, which were calculated from case-series prevalence, were applied.^[@r03]^

Incidence and mortality data of infection-related cancer
--------------------------------------------------------

The cancer-specific sex-stratified incidence and mortality in each country were obtained from GLOBOCAN 2012 and a cancer register project (cancer incidence of Japan).^[@r09]^ The numbers of new cases of cancer and cancer-related deaths that were attributable to infection were estimated by multiplying the overall numbers of new cases of cancer and cancer-related deaths with the corresponding PAF. The data of anal cancer, penile cancer, vulvar cancer, and vaginal cancer were included in the category of others and unspecified cancers in the GLOBOCAN project. Therefore, we referred to *Cancer Incidence in Five Continents Vol. X* (CI5X),^[@r10]^ which recorded cancer-sorted incidence data worldwide from 2003 to 2007, to estimate the proportions of these cancers. For countries which were not listed in the CI5X (Bangladesh, Indonesia, Vietnam, Iran, and Saudi Arabia), we assumed geographic similarity of cancer incidence patterns in the same area of Asia. For example, Bangladesh is located in Middle South Asia, so the cancer incidence data was assumed to be consistent with that of Pakistan.

Specific data on incidence and mortality related to noncardia and cardia gastric cancer, hepatocellular carcinoma, and cholangiocarcinoma in Korea was obtained in an original article^[@r11]^ because the national registry was of high quality with broader categories than those of GLOBOCAN 2012.

It was assumed that Burkitt's lymphoma accounted for 2.6% of the total non-Hodgkin's lymphoma (NHL) cases in East/Southeast Asia (however, the proportion in Japan is assumed to be \<0.1%) and 14.8% in West Asia. In developing areas of Asia, noncardia gastric cancer constituted 80.0% and 87.0% of gastric cancers in men and women, respectively, while in developed areas, the respective proportions were 80.0% and 88.0%.^[@r04]^ We assumed the proportions of hepatocellular carcinoma and cholangiocarcinoma in liver cancer to be 80% and 15%, respectively. The assumed incidence of cholangiocarcinoma was higher than the world average due to a markedly high prevalence of liver flukes in the study areas.^[@r12]^

By applying these findings to Levin's formula $\text{AF} = \frac{\text{P} \times (\text{RR} - 1)}{\lbrack\text{P} \times (\text{RR} - 1)\rbrack + 1}$ (Formula A) or $\text{AF} = \frac{(\text{RR} - 1)}{\text{RR}}\text{Pc}$ (Formula B)^[@r13]^ (where P is the prevalence of infectious agent in general population, Pc is the prevalence among patients, and RR is the RR of cancer among infectious agents exposed population), PAFs were calculated. Combining the data of cancer incidence and mortality in each country from GLOBOCAN 2012, the overall and specific numbers of new cancer cases and cancer-related mortality caused by infection were estimated. We hypothesized that infection had no effect on survival.

RESULTS
=======

Table [2](#tbl02){ref-type="table"} shows the data source of RRs applied in the current study, the biomarkers of each infectious agent, the study design, and the target population of each study. The RRs of human papillomavirus (HPV)-related anal cancer, vulvar cancer, vaginal cancer, and penile cancer were replaced with corresponding generally accepted PAFs because no data for RRs were available.^[@r14]^ Oncogenic HPV is the etiological agent of cervical cancer, while EBV and Kaposi's sarcoma-associated herpes virus/human immunodeficiency virus (KSHV/HIV-1) play vital roles in nasopharynx cancer (100.0% of nasopharynx cancers were assumed to be EBV-related in medium- and high-risk areas, and 90.0% elsewhere^[@r04]^) and Kaposi's sarcoma (the RRs were 97.5 in men and 202.7 in women, respectively).^[@r15]^ Therefore, the PAFs of these cancers were assumed to be 100. Information about the prevalence of etiologic agents in the general population of the study countries and the RRs of corresponding cancers, as well as gender-specific prevalence of infection by carcinogenic infectious agents, are shown in Table [3](#tbl03){ref-type="table"}. Table [4](#tbl04){ref-type="table"} specifies PAFs of infectious agents and cancer sites in different countries among men and women. Table [5](#tbl05){ref-type="table"} shows total estimated new cases and deaths caused by infection.

###### Summary of applied relative risks and data sources

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer site                Infectious agent             Relative risk       Data source                                                           
  -------------------------- ---------------------------- ------------------- ------------------- --------------------------- --------------------- ---------------------------
  Oral cavity                HPV                          2.0 (1.2--3.4)      2.0 (1.2--3.4)      HPV L1 antibody or\         Meta-analysis         International \[[@r16]\]\
                                                                                                  HPV-DNA (tumor tissue)                            1656 cases

  Oropharynx                 HPV                          12.3 (5.4--26.4)    12.3 (5.4--26.4)    HPV-DNA (tumor tissue)      Case-control study    USA \[[@r17]\]\
                                                                                                                                                    100/200

  Nasopharynx                EBV                          PAF 90^a^           PAF 90^a^           EBV-DNA (tumor tissue)      Review                International \[[@r04]\]

  Noncardia stomach          HP                           5.9 (3.4--10.3)     5.9 (3.4--10.3)     Anti-HP antibody (blood)    Meta-analysis         International \[[@r18]\]

  Cardia stomach             HP                           1.6 (1.0--2.5)      1.6 (1.0--2.5)      Anti-HP antibody (blood)    Meta-analysis         International \[[@r19]\]

  Anus                       HPV                          PAF88               PAF88               HPV DNA (tumor tissue)      Meta-analysis         International \[[@r20]\]

  Hepatocellular carcinoma   HBV                          18.1 (10.7--28.8)   18.1 (10.7--28.8)   HBsAg (blood)               Meta-analysis         China \[[@r21]\]

                             HCV                          13.1 (5.3--27.0)    13.1 (5.3--27.0)    Anti-HCV antibody (blood)   Meta-analysis         China \[[@r21]\]

  Cholangiocarcinoma         Clonorchis sinensis          4.7 (2.2--9.8)      4.7 (2.2--9.8)      Fluke egg (stool)           Meta-analysis         Korea \[[@r22]\]

                             HBV                          2.7 (2.0--3.6)      2.7 (2.0--3.6)      HBsAg (blood)               Meta-analysis         International\
                                                                                                                                                    (mainly Asian)\
                                                                                                                                                    \[[@r23]\] 3387/98 428

                             HCV                          5.2 (2.1--12.8)     5.2 (2.1--12.8)     Anti-HCV antibody\          Case-control study    USA \[[@r24]\]\
                                                                                                  or HCV RNA (blood)                                625/90 834

                             *Opisthorchis* *viverrini*   14.1                14.1                Fluke egg (feces)           Cross-section study   Thailand\
                                                                                                                                                    \[[@r25]\] 12 311

  Vulva                      HPV                          ---                 PAF 43              HPV DNA (tumor tissue)      Meta-analysis         International \[[@r20]\]

  Vagina                     HPV                          ---                 PAF 70              HPV DNA (tumor tissue)      Meta-analysis         International \[[@r20]\]

  Cervix uteri               HPV                          ---                 PAF 100             HPV DNA (tumor tissue)      Meta-analysis         International \[[@r20]\]

  Penis                      HPV                          PAF 50              ---                 HPV DNA (tumor tissue)      Meta-analysis         International \[[@r20]\]

  Hodgkin's lymphoma         EBV                          PAF 46              PAF 46              EBV-DNA (tumor tissue)      Review                International \[[@r04]\]

  Non-Hodgkin's lymphoma     HIV-1                        37.4 (36.0--39.0)   54.6 (16.1--60.7)   Not informed                Case-control study    USA \[[@r26]\]\
                                                                                                                                                    2434/110 295

                             HCV                          2.5 (2.1--3.0)      2.5 (2.1--3.0)      Anti-HCV antibody and/or\   Meta-analysis         International \[[@r27]\]\
                                                                                                  HCV RNA (blood)                                   4169/6997

  Burkitt's lymphoma         EBV                          3.9 (2.3--6.8)      3.9 (2.3--6.8)      VCA IgG (blood)             Case-control study    Uganda \[[@r28]\]\
                                                                                                                                                    173/102

  Kaposi's sarcoma           KSHV/HIV-1                   PAF 100             PAF 100             Not informed                Review                International \[[@r15]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EBV, Epstein-Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; HPV, human papillomavirus; KSHV, Kaposi's sarcoma herpes virus (also known as Human herpes virus type 8).

^a^PAF is assumed to be 100 in China (high nasopharyngeal carcinoma rate).

###### Gender-specific prevalence of infectious agents in the general population and data source, by country

  Country        HPV    *Helicobacter pylori*   HIV-1     HCV        HBV        Source                                
  -------------- ------ ----------------------- --------- ---------- ---------- -------- -------- --------- --------- --------------------------------------------------------------
  Korea          8.5    47.2                    45.9      0.03^a^    0.03^a^    1.7      2.2      9.1       7.1       \[[@r29]\]\[[@r30]\]\[[@r12]\]\[[@r31]\]\[[@r12]\]
  China          17.7   56.2^a^                 56.2^a^   0.04       0.01       3.1      3.3      11.3      8.2       \[[@r32]\]\[[@r33]\]\[[@r34]\]\[[@r35]\]
  Japan          11.0   65.1^a^                 65.1^a^   \<0.1^a^   \<0.1^a^   0.9^a^   0.9^a^   0.7       0.5       \[[@r36]\]\[[@r37]\]\[[@r38]\]\[[@r39]\]\[[@r40]\]
  Indonesia      11.4   12.8^b^                 12.8^b^   \<0.1^a^   \<0.1^a^   2.1^a^   2.1^a^   5.5^a^    5.5^a^    \[[@r41]\]\[[@r42]\]\[[@r43]\]\[[@r44]\]\[[@r38]\]\[[@r45]\]
  Philippines    4.4    71.9^b^                 71.9^b^   \<0.1^a^   \<0.1^a^   0.4^a^   0.4^a^   13.3^a^   13.3^a^   \[[@r46]\]\[[@r47]\]\[[@r38]\]\[[@r48]\]\[[@r49]\]
  Thailand       6.3    53.7^a^                 53.7^a^   2.0^a^     2.0^a^     1.7^a^   1.7^a^   10.0      8.0       \[[@r50]\]\[[@r51]\]\[[@r38]\]\[[@r52]\]\[[@r53]\]
  Vietnam        8.6    72.0                    76.6      \<0.1^a^   \<0.1^a^   2.9^a^   2.9^a^   15.0      10.7      \[[@r54]\]\[[@r55]\]\[[@r38]\]\[[@r56]\]\[[@r57]\]
  Bangladesh     NA     91.7^a^                 91.7^a^   \<0.1^a^   \<0.1^a^   0.5^a^   0.5^a^   6.7       5.9       \[[@r58]\]\[[@r38]\]\[[@r59]\]\[[@r60]\]
  India          7.0    75.8^a^                 75.8^a^   0.4^a^     0.4^a^     1.5^a^   1.5^a^   4.0^a^    4.0^a^    \[[@r61]\]\[[@r62]\]\[[@r38]\]\[[@r63]\]\[[@r64]\]
  Iran           6.8    59.5                    47.7      \<0.1^a^   \<0.1^a^   0.3^a^   0.3^a^   1.9       1.5       \[[@r65]\]\[[@r66]\]\[[@r67]\]\[[@r68]\]
  Pakistan       2.8    73.5                    75.4      \<0.1^a^   \<0.1^a^   4.7^a^   4.7^a^   5.0^a^    5.0^a^    \[[@r69]\]\[[@r70]\]\[[@r38]\]\[[@r71]\]\[[@r72]\]
  Turkey         4.2    51.8^a^                 51.8^a^   \<0.1^a^   \<0.1^a^   1.2      1.8      6.5^a^    6.5^a^    \[[@r73]\]\[[@r74]\]\[[@r38]\]\[[@r75]\]\[[@r76]\]
  Saudi-Arabia   5.6    75.8^a^                 75.8^a^   \<0.1^a^   \<0.1^a^   5.1^a^   5.1^a^   2.6^a^    2.6^a^    \[[@r77]\]\[[@r78]\]\[[@r38]\]\[[@r79]\]\[[@r80]\]

HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; HPV, human papillomavirus. NA, no available data.

^a^Sex-stratified prevalence was replaced by overall prevalence.

^b^The prevalence was among patients. Formula b was used when calculating PAFs.

###### The PAFs of infectious agents and cancer sites in 13 Asian countries, by gender

  Cancer sites               Infectious agents       Male        Female
  -------------------------- ----------------------- ----------- -----------
  Oral cavity                HPV                     0%--15%     0%--15%
  Oropharynx                 HPV                     1%--37%     1%--37%
  Nasopharynx                EBV                     90%--100%   90%--100%
  Noncardia gastric cancer   *Helicobacter pylori*   11%--82%    11%--82%
  Cardia gastric cancer      *Helicobacter pylori*   7%--33%     7%--35%
  Anus                       HPV                     88%--90%    88%--90%
  Hepatocellular carcinoma   HBV                     11%--72%    8%--69%
                             HCV                     3%--38%     3%--38%
  Cholangiocarcinoma         *Clonorchis sinensis*   1%--70%     1%--70%
                             HBV                     1%--18%     1%--18%
                             HCV                     1%--18%     1%--18%
  Penis                      HPV                     50%          
  Vulva                      HPV                                 43%
  Vagina                     HPV                                 70%
  Cervix uteri               HPV                                 100%
  Hodgkin's lymphoma         EBV                     46%         46%
  Non-Hodgkin's lymphoma     HIV-1                   1%--42%     0%--52%
                             HCV                     0%--7%      0%--7%
  Burkitt's lymphoma         EBV                     20%         20%
  Kaposi's sarcoma           KSHV/HIV                100%        100%

EBV, Epstein-Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; HPV, human papillomavirus; KSHV, Kaposi's sarcoma herpes virus (also known as Human herpes virus type 8).

###### Estimated new cancer cases and deaths caused by infection in 2012, by country

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country        Estimated new cases\   All new   Percentage\   Estimated deaths\     All cancer-related deaths^a^   Percentage\                                   
                 caused by infection              %             caused by infection                                  %                                             
  -------------- ---------------------- --------- ------------- --------------------- ------------------------------ ------------- --------- --------- ----------- -------
  Korea          24 820                 14 358    39 178        39 178                17.8%                          10 810        5986      16 796    81 510      20.6%

  China          444 493                233 869   678 207       678 362               22.1%                          383 591       183 257   566 848   2 205 946   25.7%

  Japan          57 409                 37 710    95 119        95 119                13.5%                          27 307        17 569    44 876    378 636     11.9%

  Indonesia      18 626                 28 778    47 404        47 404                15.8%                          15 649        15 133    30 783    194 528     15.8%

  Philippines    5581                   9511      15 091        15 091                15.4%                          4681          5115      9796      59 012      16.6%

  Thailand       10 681                 13 376    24 057        24 057                19.4%                          9270          8713      17 984    84 981      21.2%

  Vietnam        25 951                 15 098    41 049        41 049                32.8%                          23 152        11 036    34 188    94 743      36.1%

  Bangladesh     5882                   15 220    21 102        21 102                17.2%                          5197          9471      14 668    91 339      16.1%

  India          60 415                 153 094   213 509       213 509               21.0%                          52 251        93 076    145 327   682 830     21.3%

  Iran           5402                   3622      9024          9024                  10.6%                          4321          2460      6781      53 350      12.7%

  Pakistan       5733                   8711      14 444        14 444                9.8%                           4917          5790      10 707    101 113     10.6%

  Turkey         6109                   5758      11 867        11 867                8.0%                           4774          3885      8659      91 826      9.4%

  Saudi Arabia   1021                   799       1819          1819                  10.4%                          687           449       1136      9134        12.4%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA, data not available.

^a^Excluding non-melanoma skin cancer (C44).

Overview
--------

Among six principle infectious agents, the most new cancer cases were attributed to HP (31.5%), followed by HBV (28.6%), and HPV (22.0%). This trend was slightly different for deaths; 32.8% of deaths from cancer attributed to major infectious agents were attributed to HP, while 27.3% of such deaths were attributed to HPV and 23.8% to HBV. Overall, the principle infectious agents caused 19.6% of new cancer cases and 22.0% of cancer deaths in the study areas. [Figure](#fig01){ref-type="fig"} illustrates different patterns of cancer incidence and death caused by infectious agents in both sexes.

![Proportion of estimated new cancer cases and deaths attributable to different infectious agents in men and women.](je-25-626-g001){#fig01}

Human papillomavirus
--------------------

The high-risk genotypes (mainly types 16 and 18) of human papillomavirus are causative agents of up to 100% of cervical cancers, around 50% of penile cancers, 70% of vaginal cancers, 43% of vulvar cancers, 88% of anal cancers, 25% of oral cancers, and 35% of oropharyngeal cancers (especially lingual tonsillar cancers). Therefore, the PAFs of cervical cancer, anal cancer, penile cancer, vaginal cancer, and vulvar cancer were set at 100, 88, 50, 70, and 43, respectively.^[@r14]^ When it comes to oral cavity and oropharyngeal cancers, the correlations are less remarkable (HPV is positively detected in 20%--40% of cases^[@r81]^), and PAFs varied with prevalence of high-risk genotypes of HPV in different countries. HPV contributed to 29 324 and 275 429 new cancer cases and 20 613 and 141 612 deaths in men and women, respectively. Table [6](#tbl06){ref-type="table"} illustrates the new cancer cases and deaths due to HPV infection.

###### Estimated new cancer cases and deaths attributed to HPV in 2012, by country

  Country                    Oral cavity   Oropharynx   Anus   Penis   Cervix uteri   Vulva   Vagina   Percentage^a^                   
  -------------- ----------- ------------- ------------ ------ ------- -------------- ------- -------- --------------- ------ -------- --------
  Korea          New cases   29            18           99     10      153            157     42       3299            59     66       61.01%
  Deaths         10          5             44           4      39      46             18      1113     17              19     58.97%   
  China          New cases   2054          1167         2007   398     1193           876     1529     61 691          1171   1028     73.68%
  Deaths         1108        596           1312         333    644     494            1199    29 526   732             642    70.86%   
  Japan          New cases   484           339          1300   158     443            386     169      9390            246    186      51.81%
  Deaths         217         179           737          97     179     187            91      2712     131             99     42.53%   
  Indonesia      New cases   307           238          404    152     152            157     339      20 928          160    169      76.86%
  Deaths         129         101           321          116    100     104            251     9498     91              97     74.88%   
  Philippines    New cases   53            47           101    52      46             43      47       6670            45     56       70.12%
  Deaths         22          19            84           46     27      24             33      2832     23              29     62.17%   
  Thailand       New cases   128           92           187    37      59             77      212      8184            177    66       64.55%
  Deaths         66          47            118          23     35      46             162     4513     107             40     64.74%   
  Vietnam        New cases   110           60           251    46      43             56      172      5146            54     57       64.68%
  Deaths         50          27            202          36     30      38             144     2423     36              38     60.83%   
  Bangladesh     New cases   214           103          972    223     180            122     172      11 956          54     57       42.14%
  Deaths         123         59            831          191    132     90             144     6582     36              38     37.66%   
  India          New cases   3536          1521         5976   1310    2571           1863    2564     122 844         806    1962     57.21%
  Deaths         2393        1027          5085         1089   1937    1412           1915    67 477   489             1190   51.61%   
  Iran           New cases   49            39           23     17      147            85      0        947             7      35       46.94%
  Deaths         16          13            16           12     87      50             0       370      4               20     50.39%   
  Pakistan       New cases   20            16           17     8       219            149     341      5233            127    309      28.58%
  Deaths         11          9             14           7      159     110            260     2876     79              192    27.09%   
  Turkey         New cases   38            23           39     11      89             79      10       1686            93     42       51.68%
  Deaths         13          8             28           8      53      47             7       663      49              23     51.97%   
  Saudi Arabia   New cases   10            9            6      5       16             22      2        241             4      7        43.75%
  Deaths         3           2             4            3      9       12             1       84       2               3      47.31%   

^a^The proportion of HPV-induced new cancer cases/deaths in all corresponding new cases/deaths.

Epstein-Barr virus
------------------

The PAF of nasopharyngeal carcinoma caused by EBV was 90 in most Asian regions.^[@r04]^ In Southern China, an area with a high nasopharyngeal carcinoma burden, the fraction was assumed to be 100, which means that all cases of nasopharyngeal cancer and related deaths were attributable to EBV. According to the GLOBOCAN 2012 report,^[@r82]^ EBV resulted in 59 553 new nasopharyngeal cancer cases and 35 862 deaths in the target countries, with a gender ratio around 2:1. The top three countries that have the greatest burden of nasopharyngeal cancer caused by EBV in 2012 were China (33 198 new cases and 20 404 deaths), Indonesia (11 776 new cases and 6652 deaths), and Vietnam (4438 new cases and 2597 deaths). Furthermore, 8913 new cases and 6724 deaths related to Hodgkin's lymphoma were attributed to EBV in 2012. As for EBV-related Burkitt's lymphoma, there were 772 new cases and 464 deaths in the 13 countries analyzed.

Human immunodeficiency virus type 1
-----------------------------------

The early 1990s saw the initial proliferation of human immunodeficiency virus type 1 (HIV-1) in Asia, and the seroprevalence of HIV in Asian countries was consequently low (\<0.1%). Cases were sporadic, except for several countries and sites, such as Thailand and India, which experienced a relatively high burden of HIV (0.22%--2%).^[@r38],[@r83],[@r84]^ In 2012, 8089 NHL cases and 929 Kaposi's sarcoma cases were attributed to HIV infection, with 5227 and 494 respective deaths. In India, there were 3417 new NHL cases and 19 new Kaposi's sarcoma cases, making India the country with the highest HIV-related cancer burden in Asia. Although the HIV prevalence rate in the general population was highest in Thailand, there was less overall burden (39 new Kaposi's sarcoma cases and 1832 new NHL cases) because of its small total population. Although most cases of anal cancer were related to high-risk type HPV, HIV also contributed to the anal cancer burden, due to immune suppression caused by the HIV infection.

Hepatitis B virus and hepatitis C virus
---------------------------------------

Asia has a heavy disease burden from hepatitis B virus (HBV) and hepatitis C virus (HCV), both of which contribute to hepatocellular carcinoma and cholangiocarcinoma. Moreover, HCV is related to NHL. Table [7](#tbl07){ref-type="table"} lists the numbers of new cases and deaths from cancers resulting from HCV and HBV infection in the target countries.

###### Estimated new cancer cases and death caused by HBV and HCV in 2012, by country

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                    Hepatocellular\   Cholangio-\   Hepatocellular\   Cholangio-\   Non-Hodgkin's\   Percentage^a^                                 
                             carcinoma\        carcinoma\    carcinoma\        carcinoma\    lymphoma\                                                      
                             HBV-related       HBV-related   HCV-related       HCV-related   HCV-related                                                    
  -------------- ----------- ----------------- ------------- ----------------- ------------- ---------------- --------------- ------ ------ ------ -------- --------
  Korea          New cases   6670              2428          355               90            1481             654             38     16     64     68       54.88%

  Deaths         3824        1330              461           120               849           358              50              21     23     22     50.83%   

  China          New cases   154 616           47 390        6965              1829          64 048           23 174          5069   1852   1160   778      70.17%

  Deaths         148 545     47 366            6692          1828              61 533        23 162           4870            1852   738    466    72.51%   

  Japan          New cases   2461              975           12                5             2163             1145            37     20     144    132      12.41%

  Deaths         2178        828               11            4                 1914          972              33              17     80     67     14.29%   

  Indonesia      New cases   5174              1841          168               60            2168             771             162    58     237    170      34.37%

  Deaths         4899        1750              159           57                2052          733              154             55     31     115    45.61%   

  Philippines    New cases   3021              1273          148               62            211              89              14     6      8      7        48.14%

  Deaths         2916        1211              142           59                203           84               14              6      5      4      52.43%   

  Thailand       New cases   3902              1385          1217              389           1077             418             582    226    56     44       38.09%

  Deaths         3705        1320              1156          370               1023          398              553             215    39     30     39.77%   

  Vietnam        New cases   9671              2678          503               117           3496             1077            274    84     65     46       73.01%

  Deaths         9199        2545              478           111               3326          1024             260             80     45     32     75.11%   

  Bangladesh     New cases   781               475           27                16            84               54              6      4      11     6        27.58%

  Deaths         741         455               26            15                80            52               5               3      8      5      30.33%   

  India          New cases   5591              3302          161               95            2108             1245            152    90     347    173      25.90%

  Deaths         5435        3246              156           93                2049          1224             148             88     242    121    29.52%   

  Iran           New cases   174               110           4                 2             21               16              1      1      7      5        7.07%

  Deaths         166         105               4             2                 20            15               1               1      5      3      9.26%    

  Pakistan       New cases   1040              552           32                17            819              435             70     37     245    148      33.00%

  Deaths         987         528               31            16                778           416              66              35     179    109    37.05%   

  Turkey         New cases   646               290           22                10            156              99              11     7      51     56       18.63%

  Deaths         613         277               21            10                148           94               10              7      31     34     23.94%   

  Saudi Arabia   New cases   126               50            3                 1             157              63              14     5      51     37       25.76%

  Deaths         118         48                3             1                 148           60               13              5      28     21     32.39%   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

HBV, hepatitis B virus; HCV, hepatitis C virus.

^a^The proportion of HBV- and HCV-induced new cancer cases/deaths in all these cancers cases/deaths.

Helicobacter pylori
-------------------

The cases and deaths of gastric cancer caused by HP are shown in Table [8](#tbl08){ref-type="table"}.

###### Estimated new cases and deaths of HP-related gastric cancer in 2012, by country

  Country        Noncardia gastric cancer   Cardia gastric cancer   Percentage^a^                                                     
  -------------- -------------------------- ----------------------- --------------- -------- -------- ------ -------- ------ -------- --------
  Korea          13 705                     6880                    4439            2657     1404     367    455      142    71.50%   71.59%
  China          166 389                    78 450                  129 994         66 944   14 122   3632   11 033   3099   64.84%   64.91%
  Japan          45 048                     22 728                  19 613          11 337   4104     1129   1787     563    67.66%   67.78%
  Indonesia      324                        203                     292             183      54       20     48       18     10.00%   10.01%
  Philippines    673                        523                     571             441      75       35     64       29     54.08%   54.09%
  Thailand       933                        776                     751             625      77       39     249      31     64.24%   72.44%
  Vietnam        5863                       3295                    5355            2981     561      194    512      176    69.80%   69.79%
  Bangladesh     2653                       1799                    2497            1675     285      115    268      107    73.70%   73.70%
  India          27 346                     13 511                  25 666          12 557   2681     792    2517     736    70.26%   70.25%
  Iran           3955                       1840                    3374            1573     345      86     294      74     64.45%   64.45%
  Pakistan       1508                       980                     1408            913      146      57     136      53     70.08%   70.05%
  Turkey         3408                       2610                    2918            2232     278      127    238      109    63.47%   63.46%
  Saudi Arabia   212                        134                     172             110      21       8      17       6      70.62%   70.28%

^a^The proportion of HP-related gastric cancer cases/deaths in all gastric cancer cases/deaths.

DISCUSSION
==========

The present study is the first to assess the burden of potentially oncogenic infections and their related cancers in Asia. Based on the methods of previous studies in China^[@r85]^ and Korea,^[@r11]^ the nation-specific data of prevalence of infections by oncogenic agents and the general population RRs of infection-related cancers were collected for PAF calculation. Additionally, we estimated the cancer burden attributable to infection in 13 Asian countries using the numbers of new cancer cases and deaths provided in GLOBOCAN2012. Overall, we estimated that 1 212 026 new cancer cases (19.6% of all cancers) and 908 549 deaths (22.0% of all cancer-related deaths) were caused by infection in 2012. Parkin's study in 2002^[@r04]^ estimated that infectious agents were responsible for 17.8% of cancer cases worldwide (26.3% of cases in developing countries and 7.7% of cases in developed countries). Our results were somewhat different from previous nation-specific PAF calculations^[@r11],[@r85]^ because most of the RRs in our study were summarized from international studies that were generalizable to different Asian countries; for example, we chose the RR of 18.8 for HBV, which was taken from a study with a large sample size,^[@r21]^ rather than the RRs in Shin's study^[@r11]^ (24.45 in men and 33.73 in women), which were taken from a meta-analysis of Korean data and only represented the Korean population. Moreover, we estimated the number of cancers based on GLOBOCAN2012, while previous studies used Korean data from 2007. This earlier data found lower prevalence than those of GLOBOCAN2012, and the proportion of infection-related cancers in all cancers was consequently lower. However, our results are consistent with Parkin's estimates for developing countries because the majority of countries in our study are developing countries (except for Japan and Korea). Specifically, 20.5% of new cancer cases were related to infection in the 11 developing Asian countries, and 14.5% of new cancer cases were related to infection in Korea and Japan. Because the background prevalence of infectious agents in Korea and Japan differed from other developed areas (mainly Europe and North America), the proportion of infection-related cancers in developed countries was doubled in our study.

Another study in 2008^[@r03]^ revealed that 16.1% of new cancer cases were attributed to infection worldwide, and the proportion was higher in less developed countries (22.9%) than in more developed countries (7.4%). While both Parkin's and Martel's studies focused on global infection-related cancer burden, our study is designed in a region-specific way, in which we analyzed the data from 13 Asian countries to illustrate the infection background of cancer cases and deaths in Asia in 2012. The findings of our study provide comparable data for different Asian countries, which enable us to gain insight into the regional status of infectious agents that are linked to cancer incidence. The potential burden of disease (BOD) described in the Asian region could be significantly ameliorated with intervention measures, such as prophylactic vaccinations for HBV and HPV. In addition, this description of the BOD offers a baseline reference for governments seeking to address the public health issues of infectious disease and cancer. Combining the outcomes of the current study with the data of medical expenses and living expenditures of corresponding countries, the economic burden caused by infection could be calculated. These economic burden calculations can illustrate to policymakers the importance of taking immediate action on infection control for these agents, which may improve the living standard of the public, reduce unnecessary loss of lives, and reduce financial burden.

The gender-specific patterns of incidence and mortality caused by different infectious agents (shown in [Figure](#fig01){ref-type="fig"}) are of practical consequence when designing preventive interventions and treatment for targeted population. For men, HP and HBV are the main causative factors of gastric cancer and liver cancer, respectively, together comprising over three quarters of infection-related cancer cases and deaths. HBV infection contributes to twice the liver cancer burden in men as in women, and much work remains to reduce the high prevalence of HBV in Southeast/East Asia. In women, HPV and HP were associated with heavy burden of cervical and gastric cancers, respectively. These findings indicate that more attention should be paid to prevention of HPV in women, and both prevention and treatment of HP play vital roles in reducing cancer burden in Asia for both genders.

HIV
---

Although infection with HIV alone will not cause many common HIV-associated cancers, it has been recognized as a major contributing factor to some specific cancers because cancer incidence rises significantly with combined infection of HIV and strong cancer-causing infectious agents. The carcinogenic mechanisms of HIV are immune deficiency and suppression, which lead to the failure of immunological surveillance of tumor cells and susceptibility to carcinogenic factors. The contribution of HIV to the development of many cancers is complicated; for example, HIV can increase the risk of anal cancer, which is caused by HPV. To avoid over-counting for these co-infections, we only estimated cases and deaths of Kaposi's carcinoma and NHL, in which HIV plays a main role, though in comparison to European or North American countries, the prevalence of Kaposi's carcinoma in Asia is quite low.^[@r15]^ The numbers of cancer cases and deaths related to HIV infection might be overestimated because we considered the estimated prevalence of HIV in low-prevalence areas as 0.1%, while UNAIDS^[@r38]^ reported prevalence below 0.1% in the general population. The current study estimates that HIV contributed to 9018 new cases and 5721 deaths from cancer in the study area. However, the rates of HIV infection started to rise after the low-prevalence stage of the early 1990s, increasing from 0.1% to 1.3% in 2009.^[@r83]^ The pattern of HIV spread in Asia has gradually changed, from sporadic new cases in the general population and epidemic in high-risk groups to a low-level epidemic in the general population. As a consequence, the numbers of HIV-associate cancer cases and deaths is expected to increase in a few years, especially in regions such as Thailand and India. The HIV prevalence of these areas is much higher than in the rest of the surveyed Asian countries, which is expected to cause health and social problems, including short lifespan and poverty. Fortunately, the utilization of antiretroviral therapy and behavioral interventions in Asian areas have had initial success in reducing costs of HIV control.^[@r83]^ However, much work is still required to control the spread of HIV in developing countries.

HP
--

There has been controversy over the direct evidence linking HP infection and gastric cancer in Asia,^[@r78]^ where there is some doubt that the high infection rate of HP (eg, in Japan and Bangladesh^[@r58]^) is a predictor of the high prevalence of gastric cancer. At an individual level, HP has been associated with the occurrence of gastric cancer, but some Asian countries have a low prevalence of gastric cancer despite a high HP prevalence. Alcohol and cigarette consumption in these areas may cause many of these gastric cancers. However, a Japanese study^[@r40]^ revealed that both groups testing strongly positive and weakly positive for HP antibody showed significantly higher incidence of gastric cancer compared to those testing negative. We adopted a combined analysis, which illustrated that the OR for non-cardia gastric cancer and HP was 5.9 (95% CI, 3.4--10.3) compared with those testing negative for HP,^[@r18]^ while the relationship was less significant between cardia gastric cancer and HP infection (RR1.6; 95% CI, 1.0--2.5).^[@r19]^ Consequently, we estimated that approximately 436 501 new cancer cases and 324 042 deaths were caused by HP in 2012. The use of regular and rational combinations of antibiotics is the optimal secondary prevention strategy against HP infection, but such use of antibiotics is the primary prevention method for gastric cancer. Using regular gastroscope screening tests, early lesions on the gastric epithelium can be detected before they progress to cancer.^[@r86]^

HPV
---

In our study, new cancers in the oral cavity, oropharynx, cervix, vulva, and vagina that were associated with high-risk types of HPV totaled 278 403 cases, ranking HPV the highest among the principle infectious cancer-causing agents in women. HPV was also estimated to be responsible for 162 762 cancer deaths in Asia, making HPV the second-ranked infectious factor leading to cancer deaths. To estimate the burden of HPV-related vulvar, vaginal, penile, and anal cancers, we applied a geographic similarity method in cases where country-level data was not available in CI5X. Namely, neighboring countries' data were used to substitute for the corresponding incidence or mortality of the country with missing data. Admittedly, this method has some limitations, because the incidence and mortality of cancers vary by country. However, it is likely to be a more accurate way of estimating the sub-category cancer burden with the present database than by assuming the same incidence and mortality across Asia without considering geographic factors.

Since the currently licensed prophylactic HPV vaccines (Gardasil for type 6, 11, 16, and 18 and Cervarix for type 16 and 18) marketed in North America, Europe, Australia,^[@r87]^ and some parts of Asia became available, the expectation is that HPV-related cancers maybe largely prevented if these vaccines are adopted with high coverage. Both vaccines have been shown to be effective, immunogenic, and safe.^[@r88]^ However, the vaccines have not been approved to market in most areas of Asia. Where they are approved, such as Hong Kong and Korea, they are high-priced and less likely to be listed in social medical insurance, therefore largely only available to those who can afford them. Where governments have endorsed and paid for vaccines, such as in Australia,^[@r87]^ reductions in rates of HPV-related infections^[@r89]^ and high-grade lesions (ie, lesions coded as cervical intraepithelial neoplasia of grade 2 or worse or adenocarcinoma in situ)^[@r90]^ have already been seen. The vaccines are currently accessible through school-based government-funded programs only in a few regions, such as Malaysia, Bhutan, and Japan. The predicted outcome is that the HPV-related cancer burden will decline if the primary prevention measure of HPV vaccines is applied in the general population by governments. In addition, screening with cytology tests, visual inspection, or HPV-DNA detection are practical secondary prevention methods that can be employed against cervical cancer in low-resource countries and areas.

HCV and HBV
-----------

HCV and HBV were highly epidemic up to the early 1990s in many areas of Asia, resulting in a relatively high incidence of liver cancer decades later. However, the late 1990s saw the introduction of the HBV vaccine among all newborns, particularly babies of women who were chronically infected with HBV. Widespread HBV vaccination has been markedly effective in reducing the HBV epidemic in areas where good coverage has occurred. A Taiwanese study showed that universal HBV vaccination for newborns provided long-term protection for up to 20 years, which enabled prevention of the infection before adulthood^[@r91]^; meanwhile, obligatory screening of blood and organ donations has significantly curbed HCV transmission. Together, HBV and HCV caused 431 086 new liver cancer cases and 406 779 deaths in 2012, representing 77.61% of liver cancer cases and 76.6% of deaths. In addition, liver flukes, such as *Clonorchis sinensis* and *Opisthorchis viverrini*, were also causal factors of liver cancer (responsible for 1701 new cholangiocarcinoma cases in our estimation). *C. sinensis* is still an endemic parasite in areas of river basins in East Asia, while *O. viverrini* remains epidemic in Thailand.^[@r04],[@r92]^ In this case, improving public awareness of the risk of the consumption of raw or insufficiently cooked fish, management of fecal sewage, and the supervision of intermediate hosts in epidemic areas are of great importance in controlling fluke infection and preventing related liver cancers.

Inevitably, our study has some limitations. First, not all prevalence data of infectious agents in the target countries were available. For instance, the prevalence of EBV in most countries and the prevalence of HPV in Bangladesh were not readily available from the databases to which we had access. We used overall PAFs for the cancers caused by EBV in all target countries and PAFs of HPV in Bangladesh. Moreover, the RRs we adopted are not country-specific, except for some RRs taken from independent studies on infection-related cancer burden in Korea^[@r10]^ and China.^[@r85]^ Numbers of cancer deaths in Japan were taken from the data of Monitoring Cancer Incidence in Japan (MCIJ) Project. The mortality data reported in MCIJ were lower than those in GLOBOCAN 2012, and we recognized them as more reliable and valid due to the wider regions that the program covered and the high-quality systematic registration method the MCIJ Project employed. According to the proportion of cancer deaths, some cancer categories in the MCIJ report were split into the corresponding sub-categories, as in GLOBOCAN, to facilitate estimation. As we were focusing on estimated numbers of infection-related cancer cases and deaths rather than comparing cancer incidence and mortality among different countries, we did not do age or sex standardization when using two data sources. Age-standardized data were available in both the MCIJ and GLOBOCAN. Old research was used to extrapolate the prevalence within a defined period, which affected the results because older technology for detection of infectious agents was limited. In addition, the geographic similarity assumption was utilized to tackle the inaccessible proportions of other and unspecified cancers (eg, penile, vulvar, and anal cancer) of the countries not included in CI5X. The data of CI5X came from a different time period (1993--1997), and the rest of data were from 1997 to 1999. Some of the RRs were extracted from non-Asian studies if the data could not be obtained in reliable Asian studies. As a consequence, the estimations in our study ignored some geographic variation among these countries. There might be some systematic differences between larger and smaller countries in Asia. In addition, the sample sizes of some prevalence studies of infectious agents in some countries were small or contained severe bias because the subjects were blood donors or hospital-based populations rather than general populations, which makes it hard to extract valid prevalence. For example, the majority of studies of HBV and HCV prevalence in Japan were based on the registry system of blood donation,^[@r39],[@r40]^ resulting in limited representativeness. As liver flukes are endemic in a limited area in Asia and accurate data were not available, rates of cholangiocarcinoma and urinary bladder cancer caused by liver flukes were not included in our study. The exclusions of cholangiocarcinoma and urinary bladder cancers in calculating the prevalence of cancers and deaths may have caused a slight underestimation of the deaths and new cases attributable to this infection.

In conclusion, infectious factors play a major role in the etiology and progression of various cancers, which contributes to about one quarter of all cancer cases and cancer-related deaths. Infection by these agents not only results in the loss of life, but also imposes heavy economic burden on families and societies, both directly and indirectly. Adopting long-term measures (including primary and secondary prevention) to prevent infection from the principal cancer-causing agents is an efficient way to reduce rates of infection-related cancers. Tools are available to prevent many of these diseases and should be utilized.
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